NCT01536067 · REGISTRY CONDITION SEARCH

Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: TERMINATED
Registry last update: 2016-06-10

This phase II trial studies how well giving ofatumumab together with bortezomib works in treating patients with previously untreated Waldenstrom macroglobulinemia. Monoclonal antibodies, such as ofatumumab and bortezomib, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving ofatumumab together with bortezomib may be a better way to block cancer growth

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Response Rate (CR + PR + MR) of Ofatumumab in Combination With Bortezomib

→

outcome · NOT POSTED

Frequency of Complete Remission (CR)

→

outcome · POSTED

Frequency of Near (n)CR

→

outcome · POSTED

Frequency of Very Good Partial Response (VGPR)

→

outcome · POSTED

Frequency of PR

→

outcome · POSTED

Time to Progression

→

outcome · POSTED

Progression-free Survival

→

outcome · POSTED

Duration of Response

→

outcome · POSTED

Frequency and Severity of Toxicity as Graded According to the Cancer Therapeutic Evaluation Program (CTEP) Common Toxicity Criteria (CTC) Version 4.0

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Diagnosis of Waldenstrom Macroglobulinemia and presence of cluster of differentiation (CD)20+ tumor cells as determined by immune-histochemistry or flow cytometric analysis in bone marrow or representative lymphoid tissue specimen; to be deemed eligible, patients must meet at least one of the following criteria: * Rising immunoglobulin (Ig)M * Hemoglobin =\< 10 g/dL * Platelet count =\< 100 x 10\^9/L * Symptomatic or bulky lymphadenopathy or organomegaly * Systemic manifestations of Waldenstrom Macroglobulinemia (WM), such as hyperviscosity symptoms (patients with symptoms of hyperviscosity syndrome must be treated with plasmapheresis to control the syndrome prior to enrollment), neuropathy, amyloidosis, cryoglobulinemia, B-symptoms, or recurrent bleeding * Must have a measurable disease as defined by the monoclonal IgM level of 1 g/dL on serum protein electrophoresis (SPEP); if the level of IgM on SPEP is less than 1 g/dL in patients who meet any criteria in inclusion criteria 2, then the IgM level obtained from nephelometric measurement may be used to justify this criterion * Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of =\< 2 * Have a life expectancy of \>= 3 months * Absolute neutrophil count \>= 1.0 x 10\^9/L unless the result of disease infiltration of bone marrow * Platelet count \>= 50 x 10\^9/L unless the result of disease infiltration of bone marrow * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x the institutional upper limit of normal (ULN) * Total bilirubin =\< 3 mg/dL or 1.5 x institutional ULN, whichever is lower * Serum creatinine =\< 3 mg/dL * Female patients are either post-menopausal or surgically sterilized otherwise they must agree to use acceptable contraceptive methods (e.g. double barrier) during treatment * Male subjects, even if surgically sterilized (i.e., status post vasectomy) must agree to one of the following: * Practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug * Completely abstain from heterosexual intercourse * Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent prior to receiving any study related procedure Exclusion Criteria: * Pregnant and nursing female patients * Prior anti-neoplastic therapy for WM; the use of plasmapheresis to manage the symptoms of hyperviscosity and other IgM paraprotein mediated symptoms is allowed and does not disqualify a patient from the study; if a patient undergoes plasmapheresis within 8 weeks of starting the study treatment then the IgM level prior to plasmapheresis should be used for response assessment; neoplastic use of glucocorticoids is prohibited during the screening and treatment period; patients with active hyperviscosity symptoms should not be enrolled in this study unless the symptoms resolve after plasmapheresis * Unwilling or unable to follow protocol requirements * Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study drug * Received an investigational agent within 30 days prior to enrollment * Known human immunodeficiency virus (HIV) positive * Positive serology for hepatitis B (HB) defined as a positive test for hepatitis B surface antigen (HBsAg); in addition, if HBsAg is negative and hepatitis B core antibody (HBcAb) is positive, regardless of hepatitis B surface antibody (HBsAb) status, a HB deoxyribonucleic acid test will be performed and if HB DNA is positive the patient will be excluded; if a patient is HBsAg negative, HBcAb positive, and HBsAb positive, indicating past but not active infection, the patient will be included on the study * Positive serology for hepatitis C (HC) defined as a positive test for Hep C by enzyme immunoassays (EIA), in which case reflexively perform a HC recombinant immunoblot assay (RIBA) on the same sample to confirm the result * Diagnosis of a malignant disorder other than WM within 3 years of the study enrollment with the exception of completely resected non-melanoma skin cancer and successfully treated in-situ cancer * Uncontrolled infection * Hypersensitivity to bortezomib, boron, or mannitol * Grade 2 or greater peripheral neuropathy; since WM is known to cause peripheral neuropathy (PN), if, in investigator's judgement, a patient has Grade 2 PN related to WM, then he/she can be enrolled onto the study; under no circumstances patient with greater than Grade 2 PN can be enrolled * Myocardial infarction within 6 months of enrollment; New York Heart Association (NYHA) Class III or more heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias; arrhythmias requiring active therapy other than chronic stable atrial fibrillation; if a patient has an implanted cardiac pacemaker and is otherwise well can be enrolled onto this study after demonstrating normal ejection fraction and clearance from a cardiologist; at the time of screening any electrocardiographic abnormality has to be documented as not medically relevant by the investigator before the patient proceeds to the enrollment phase * Any serious medical or psychiatric illness that may interfere with participation in the study * Patients with symptoms of hyperviscosity syndrome will not be enrolled on the study until they undergo plasmapheresis that results in resolution of symptoms and optimal control of the syndrome
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
INDUCTION PHASE: Patients receive ofatumumab IV on days 1, 8, and 15 and bortezomib SC on days 8 and 15. Beginning on course 2, patients receive ofatumumab IV on days 1 and 15 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Beginning 8 weeks after course 4 of induction phase, patients receive ofatumumab IV on day 1 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
intervention Names
Biological: ofatumumab
Drug: bortezomib
Other: laboratory biomarker analysis
label
Treatment (monoclonal antibody therapy)
type
EXPERIMENTAL

interventions

arm Group Labels
Treatment (monoclonal antibody therapy)
description
Given IV
name
ofatumumab
other Names
Arzerra
HuMax-CD20
type
BIOLOGICAL
arm Group Labels
Treatment (monoclonal antibody therapy)
description
Given SC
name
bortezomib
other Names
LDP 341
MLN341
VELCADE
type
DRUG
arm Group Labels
Treatment (monoclonal antibody therapy)
description
Correlative studies
name
laboratory biomarker analysis
type
OTHER

Study design

allocation

NON_RANDOMIZED

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 3
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Assessed using the Consensus Panel recommendations from the Third International Workshop on Waldenstrom Macroglobulinemia.
measure
Overall Response Rate (CR + PR + MR) of Ofatumumab in Combination With Bortezomib
time Frame
Every 28 days

secondary Outcomes

measure
Frequency of Complete Remission (CR)
time Frame
Every 28 days
measure
Frequency of Near (n)CR
time Frame
Every 28 days
measure
Frequency of Very Good Partial Response (VGPR)
time Frame
Every 28 days
measure
Frequency of PR
time Frame
Every 28 days
measure
Time to Progression
time Frame
From start of treatment to disease progression, assessed up to 12 months
measure
Progression-free Survival
time Frame
From start of treatment to disease progression or death (regardless of the cause of death), whichever comes first, assessed up to 12 months
measure
Duration of Response
time Frame
From the observation of a response to the time of disease progression, assessed up to 12 months
description
Maximum grade per participant of any AE.
measure
Frequency and Severity of Toxicity as Graded According to the Cancer Therapeutic Evaluation Program (CTEP) Common Toxicity Criteria (CTC) Version 4.0
time Frame
Every 30 days for 2 months

Full study description

brief Summary: This phase II trial studies how well giving ofatumumab together with bortezomib works in treating patients with previously untreated Waldenstrom macroglobulinemia. Monoclonal antibodies, such as ofatumumab and bortezomib, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving ofatumumab together with bortezomib may be a better way to block cancer growth
detailed Description: PRIMARY OBJECTIVES: I. Determine overall response rate (complete response \[CR\] + partial response \[PR\] + minor response \[MR\]) of ofatumumab in combination with bortezomib. SECONDARY OBJECTIVES: I. Determine complete remission (CR) rate, near (n)CR rate, very good partial response (VGPR) rate and PR rate per new criteria. II. Determine 5 year progression free survival (PFS). III. Determine time to progression and duration of response of ofatumumab in conjunction with bortezomib. IV. Determine safety of ofatumumab in combination with bortezomib. V. Conduct laboratory correlates. OUTLINE: INDUCTION PHASE: Patients receive ofatumumab intravenously (IV) on days 1, 8, and 15 and bortezomib subcutaneously (SC) on days 8 and 15. Beginning on course 2, patients receive ofatumumab IV on days 1 and 15 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Beginning 8 weeks after course 4 of induction phase, patients receive ofatumumab IV on day 1 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days, and then every 3 months for 5 years.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-dd4634c49ff04b85f550
requested nct id
NCT01536067
primary nct id
NCT01536067
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
4c929fdd8214b0c424e44d839aff2908b07c06c07d54379cf8edf4d7933ab3aa
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-dd4634c49ff04b85f550
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01536067
occurrences
context exact
NCT01536067
end
11
exact text
NCT01536067
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/175/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
6eabc22aa027794197eacdefab0c1af39391cb52f9821efa9a4c6d43a89ad040
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice